How do you manage ocular hemorrhages while on acalabrutinib for CLL?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

How does the CLL17 trial presented at ASH 2025 change current practice guidelines?

In a patient who has been receiving 1L Ibrutinib for TP53+ CLL for years with complete hematologic response but detectable MRD, is there any role to switch to the novel BTKi agents given better PFS?

4 Answers

What is your preferred 1L treatment for newly diagnosed Del(17p)/TP53 mutation, high-risk CLL?

4 Answers

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service